Employees: 11 (2023.0)Legal category: 5485Size: PMECreation date: 2019-06-05 (6 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: BUEIL (27730), Eure
SELARL PHARMACIE THERIAQUE : revenue, balance sheet and financial ratios
SELARL PHARMACIE THERIAQUE is a French company
founded 6 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in BUEIL (27730),
this company of category PME
shows in 2023 a revenue of 3.2 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - SELARL PHARMACIE THERIAQUE (SIREN 851354795)
Indicator
2025
2024
2023
2022
2021
2020
Revenue
N/C
N/C
3 199 623 €
N/C
N/C
2 523 990 €
Net income
202 832 €
238 136 €
265 645 €
270 640 €
225 327 €
1 360 €
EBITDA
N/C
N/C
361 919 €
N/C
N/C
172 726 €
Net margin
N/C
N/C
8.3%
N/C
N/C
0.1%
Revenue and income statement
In 2025, SELARL PHARMACIE THERIAQUE generates positive net income of 203 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2020-2025: 1 k€ -> 203 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
202 832 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 100%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 44%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
100.401%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
43.57%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2020
2021
2022
2023
2024
2025
Debt ratio
839.881
367.352
201.362
143.946
101.724
100.401
Financial autonomy
9.724
18.667
29.93
36.989
42.623
43.57
Repayment capacity
10.371
None
None
4.53
None
None
Cash flow / Revenue
6.461%
None%
None%
8.571%
None%
None%
Sector positioning
Debt ratio
100.42025
2023
2024
2025
Q1: 13.71
Med: 49.76
Q3: 129.07
Average
In 2025, the debt ratio of SELARL PHARMACIE THERIAQUE (100.40) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
Financial autonomy
43.57%2025
2023
2024
2025
Q1: 33.42%
Med: 53.71%
Q3: 72.08%
Average
In 2025, the financial autonomy of SELARL PHARMACIE THERIAQUE (43.6%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
Repayment capacity
4.53 years2023
2023
Q1: 0.95 years
Med: 3.58 years
Q3: 7.48 years
Average
In 2023, the repayment capacity of SELARL PHARMACIE THERIAQUE (4.53) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 169.04. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2020
2021
2022
2023
2024
2025
Liquidity ratio
171.1
176.494
239.045
244.653
173.913
169.038
Interest coverage
5.761
None
None
2.274
None
None
Sector positioning
Liquidity ratio
169.042025
2023
2024
2025
Q1: 131.03
Med: 182.29
Q3: 258.7
Average-24 pts over 3 years
In 2025, the liquidity ratio of SELARL PHARMACIE THERIAQUE (169.04) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
Interest coverage
2.27x2023
2023
Q1: 0.38x
Med: 2.71x
Q3: 6.47x
Average
In 2023, the interest coverage of SELARL PHARMACIE THERIAQUE (2.3x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution SELARL PHARMACIE THERIAQUE
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2020
2021
2022
2023
2024
2025
Operating WCR
192 429 €
0 €
0 €
261 441 €
0 €
0 €
Inventory turnover (days)
23
0
0
24
0
0
Customer payment term (days)
4
0
0
4
0
0
Supplier payment term (days)
20
0
0
22
0
0
Positioning of SELARL PHARMACIE THERIAQUE in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of SELARL PHARMACIE THERIAQUE is estimated at
3 222 010 €
(range 2 186 471€ - 5 055 778€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
2186k€3222k€5055k€
3 222 010 €Range: 2 186 471€ - 5 055 778€
NAF 5 année 2025
Valuation method used
Net Income Multiple
202 832 €
×
15.9x
=3 222 010 €
Range: 2 186 472€ - 5 055 778€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare SELARL PHARMACIE THERIAQUE with other companies in the same sector:
Frequently asked questions about SELARL PHARMACIE THERIAQUE
What is the revenue of SELARL PHARMACIE THERIAQUE ?
The revenue of SELARL PHARMACIE THERIAQUE in 2023 is 3.2 M€.
Is SELARL PHARMACIE THERIAQUE profitable?
Yes, SELARL PHARMACIE THERIAQUE generated a net profit of 203 k€ in 2025.
Where is the headquarters of SELARL PHARMACIE THERIAQUE ?
The headquarters of SELARL PHARMACIE THERIAQUE is located in BUEIL (27730), in the department Eure.
Where to find the tax return of SELARL PHARMACIE THERIAQUE ?
The tax return of SELARL PHARMACIE THERIAQUE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does SELARL PHARMACIE THERIAQUE operate?
SELARL PHARMACIE THERIAQUE operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart